Literature DB >> 3310667

The dexamethasone suppression test: an overview of its current status in psychiatry. The APA Task Force on Laboratory Tests in Psychiatry.

.   

Abstract

The dexamethasone suppression test (DST) has had unprecedented evaluation among biological tests proposed for clinical use in psychiatry. It is hypothesized to reflect pathophysiologic changes at the CNS level. The sensitivity of the DST (rate of a positive outcome, or nonsuppression of cortisol) in major depression is modest (about 40%-50%) but is higher (about 60%-70%) in very severe, especially psychotic, affective disorders, including major depression with psychotic as well as melancholic features, mania, and schizoaffective disorder. The specificity (true negative outcome) of the DST in normal control subjects is above 90%, but it varies from less than 70% to more than 90% in psychiatric conditions that often need to be separated from major affective disorders. In dementia the specificity is even lower. In addition, a number of medical conditions, including severe weight loss and use of alcohol and certain other drugs (barbiturates, anticonvulsants, and others), can produce false positive results. Positive initial DST status in major depression does not add significantly to the likelihood of antidepressant response, and a negative test is not an indication for withholding antidepressant treatment. Some recent data suggest that DST-positive depressions (cortisol nonsuppression) are less likely than DST-negative cases (cortisol suppression) to respond to a placebo. If this is confirmed, it would increase the real magnitude of the difference in treatment response between DST-positive and DST-negative depressed patients. Failure to convert to normal suppression of cortisol with apparent recovery from depression suggests an increased risk for relapse into depression or suicidal behavior. Although the clinical utility of the DST as currently understood is limited, in certain specific situations its thoughtful use may aid clinical decision making. The association of an abnormal test result with major affective disorders encourages continued research on the DST.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3310667     DOI: 10.1176/ajp.144.10.1253

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  21 in total

Review 1.  Current perspectives on the genetics of unipolar depression.

Authors:  S O Moldin; T Reich; J P Rice
Journal:  Behav Genet       Date:  1991-05       Impact factor: 2.805

2.  Screening for depression in primary care. A disease in search of a test.

Authors:  T L Schwenk
Journal:  J Gen Intern Med       Date:  1996-07       Impact factor: 5.128

3.  Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex.

Authors:  S Brooke; R Chan; S Howard; R Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 4.  Pharmacoendocrinology of major depression.

Authors:  R T Rubin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Protocol for a systematic review of the development of depression among adolescents and young adults: psychological, biological, and contextual perspectives around the world.

Authors:  Gloria A Pedersen; Zuzanna Zajkowska; Christian Kieling; Kamal Gautam; Valeria Mondelli; Helen L Fisher; Johnna R Swartz; Abiodun Adewuya; Rakesh Karmacharya; Brandon A Kohrt
Journal:  Syst Rev       Date:  2019-07-20

6.  Insomnia, postpartum depression and estradiol in women after delivery.

Authors:  Ewa Drozdowicz-Jastrzębska; Michał Skalski; Paulina Gdańska; Anna Mach; Piotr Januszko; Rafał J Nowak; Piotr Węgrzyn; Mirosław Wielgoś; Maria Radziwoń-Zaleska
Journal:  Metab Brain Dis       Date:  2017-08-08       Impact factor: 3.584

7.  The diagnosis of depression: current and emerging methods.

Authors:  Katie M Smith; Perry F Renshaw; John Bilello
Journal:  Compr Psychiatry       Date:  2012-08-15       Impact factor: 3.735

Review 8.  Issues in the taxonomy of psychopathology in mental retardation.

Authors:  S L Einfeld; M Aman
Journal:  J Autism Dev Disord       Date:  1995-04

9.  Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers.

Authors:  P Christensen; A Lolk; L F Gram; P Kragh-Sørensen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Alterations in Systemic and Cognitive Glucocorticoid Sensitivity in Depression.

Authors:  Allison E Gaffey; Erin C Walsh; Charlotte O Ladd; Roxanne M Hoks; Heather C Abercrombie
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.